232 related articles for article (PubMed ID: 20117261)
21. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations.
Furuya Y; Regner M; Lobigs M; Koskinen A; Müllbacher A; Alsharifi M
J Gen Virol; 2010 Jun; 91(Pt 6):1450-60. PubMed ID: 20147516
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
Sasaki T; Isoda N; Soda K; Sakamoto R; Saijo K; Hagiwara J; Kokumai N; Ohgitani T; Imamura T; Sawata A; Lin Z; Sakoda Y; Kida H
Jpn J Vet Res; 2009 Feb; 56(4):189-98. PubMed ID: 19358446
[TBL] [Abstract][Full Text] [Related]
23. Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine.
Zhang F; Fang F; Chang H; Peng B; Wu J; Chen J; Wang H; Chen Z
Arch Virol; 2013 Jun; 158(6):1253-65. PubMed ID: 23385327
[TBL] [Abstract][Full Text] [Related]
24. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
[TBL] [Abstract][Full Text] [Related]
25. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
[TBL] [Abstract][Full Text] [Related]
27. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
[TBL] [Abstract][Full Text] [Related]
28. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.
Droebner K; Haasbach E; Fuchs C; Weinzierl AO; Stevanovic S; Büttner M; Planz O
Vaccine; 2008 Dec; 26(52):6965-74. PubMed ID: 18848593
[TBL] [Abstract][Full Text] [Related]
29. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.
Lalor PA; Webby RJ; Morrow J; Rusalov D; Kaslow DC; Rolland A; Smith LR
J Infect Dis; 2008 Jun; 197(12):1643-52. PubMed ID: 18513153
[TBL] [Abstract][Full Text] [Related]
30. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
[TBL] [Abstract][Full Text] [Related]
31. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
[TBL] [Abstract][Full Text] [Related]
32. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
[TBL] [Abstract][Full Text] [Related]
33. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
Crevar CJ; Ross TM
Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
[TBL] [Abstract][Full Text] [Related]
34. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
[TBL] [Abstract][Full Text] [Related]
35. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.
Garg S; Hoelscher M; Belser JA; Wang C; Jayashankar L; Guo Z; Durland RH; Katz JM; Sambhara S
Clin Vaccine Immunol; 2007 Jul; 14(7):926-8. PubMed ID: 17494637
[TBL] [Abstract][Full Text] [Related]
36. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
37. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
[TBL] [Abstract][Full Text] [Related]
38. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine.
Stittelaar KJ; Lacombe V; van Lavieren R; van Amerongen G; Simon J; Cozette V; Swayne DE; Poulet H; Osterhaus AD
Vaccine; 2010 Jul; 28(31):4970-6. PubMed ID: 20566392
[TBL] [Abstract][Full Text] [Related]
39. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
